Starlake Bioscience Co Inc Zhaoqing Guangdong (SHG:600866) — Market Cap & Net Worth
Market Cap & Net Worth: Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)
Starlake Bioscience Co Inc Zhaoqing Guangdong (SHG:600866) has a market capitalization of $1.16 Billion (CN¥7.93 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #8425 globally and #2069 in its home market, demonstrating a 1.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Starlake Bioscience Co Inc Zhaoqing Guangdong's stock price CN¥4.77 by its total outstanding shares 1661472616 (1.66 Billion). Review 600866 total liabilities to assess the company's total debt and financial obligations.
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap History: 2015 to 2026
Starlake Bioscience Co Inc Zhaoqing Guangdong's market capitalization history from 2015 to 2026. Data shows change from $2.00 Billion to $1.16 Billion (-4.26% CAGR).
Starlake Bioscience Co Inc Zhaoqing Guangdong Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Starlake Bioscience Co Inc Zhaoqing Guangdong's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.73x
Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap is 1.73 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.72 Billion | $679.85 Million | $24.31 Million | 2.53x | 70.82x |
| 2017 | $1.12 Billion | $686.97 Million | -$158.27 Million | 1.63x | N/A |
| 2018 | $763.41 Million | $859.11 Million | $42.28 Million | 0.89x | 18.06x |
| 2019 | $1.08 Billion | $1.05 Billion | $149.55 Million | 1.03x | 7.22x |
| 2020 | $1.21 Billion | $1.12 Billion | $148.71 Million | 1.09x | 8.16x |
| 2021 | $1.52 Billion | $4.07 Billion | $152.14 Million | 0.37x | 9.97x |
| 2022 | $1.44 Billion | $17.49 Billion | $608.33 Million | 0.08x | 2.37x |
| 2023 | $1.13 Billion | $17.37 Billion | $677.95 Million | 0.07x | 1.67x |
| 2024 | $1.57 Billion | $17.33 Billion | $943.15 Million | 0.09x | 1.67x |
| 2025 | $1.69 Billion | $15.90 Billion | $978.89 Million | 0.11x | 1.73x |
Competitor Companies of 600866 by Market Capitalization
Companies near Starlake Bioscience Co Inc Zhaoqing Guangdong in the global market cap rankings as of June 23, 2026.
Key companies related to Starlake Bioscience Co Inc Zhaoqing Guangdong by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Starlake Bioscience Co Inc Zhaoqing Guangdong Historical Marketcap From 2015 to 2026
Between 2015 and today, Starlake Bioscience Co Inc Zhaoqing Guangdong's market cap moved from $2.00 Billion to $ 1.16 Billion, with a yearly change of -4.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.16 Billion | -31.37% |
| 2025 | CN¥1.69 Billion | +7.42% |
| 2024 | CN¥1.57 Billion | +38.84% |
| 2023 | CN¥1.13 Billion | -21.42% |
| 2022 | CN¥1.44 Billion | -4.97% |
| 2021 | CN¥1.52 Billion | +25.05% |
| 2020 | CN¥1.21 Billion | +12.39% |
| 2019 | CN¥1.08 Billion | +41.40% |
| 2018 | CN¥763.41 Million | -31.74% |
| 2017 | CN¥1.12 Billion | -35.03% |
| 2016 | CN¥1.72 Billion | -13.97% |
| 2015 | CN¥2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Starlake Bioscience Co Inc Zhaoqing Guangdong was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.16 Billion USD |
| MoneyControl | $1.16 Billion USD |
| MarketWatch | $1.16 Billion USD |
| marketcap.company | $1.16 Billion USD |
| Reuters | $1.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more